MedTrace Logo

Pharmacokinetics of JULUCA in Hemodialysis

NCT04431518 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2024-06-05

Study results available
· View outcomes & findings →

Summary

This study will compare the pharmacokinetics of the component drugs in JULUCA, and HIV combination treatment pill, in HIV-negative patients who require hemodialysis with those with normal renal function.

Conditions

Interventions

DRUG

JULUCA 50Mg-25Mg Tablet

One dose of JULUCA will be taken daily for up to 14 days

Sponsors & Collaborators

  • Indiana University

    lead OTHER

Principal Investigators

  • Samir K Gupta, MD · Indiana University School of Medicine

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-04-23
Primary Completion
2023-07-31
Completion
2023-07-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04431518 on ClinicalTrials.gov